SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Peltonen Markku)
 

Sökning: WFRF:(Peltonen Markku) > A multimodal precis...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00014777naa a2200841 4500
001oai:DiVA.org:ltu-104290
003SwePub
008240215s2024 | |||||||||||000 ||eng|
009oai:DiVA.org:umu-220751
009oai:DiVA.org:kau-98616
009oai:prod.swepub.kib.ki.se:154774109
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-1042902 URI
0247 a https://doi.org/10.1186/s13195-023-01355-x2 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-2207512 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-986162 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1547741092 URI
040 a (SwePub)ltud (SwePub)umud (SwePub)kaud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Barbera, Mariagneseu Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, 70211, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, W6 8RP, UK,Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom4 aut
2451 0a A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol
264 1b BioMed Central Ltd,c 2024
338 a electronic2 rdacarrier
500 a Validerad;2024;Nivå 2;2024-04-09 (sofila);Funder: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation (ADDF); EU Joint Programme—Neurodegenerative Disease Research (JPND) EURO-FINGERS and Multi-MeMo grants; National Institutes of Health (K24AG045334);Full text license: CC BY
520 a Background: Combining multimodal lifestyle interventions and disease-modifying drugs (novel or repurposed) could provide novel precision approaches to prevent cognitive impairment. Metformin is a promising candidate in view of the well-established link between type 2 diabetes (T2D) and Alzheimer’s Disease and emerging evidence of its potential neuro-protective effects (e.g. vascular, metabolic, anti-senescence). MET-FINGER aims to test a FINGER 2.0 multimodal intervention, combining an updated FINGER multidomain lifestyle intervention with metformin, where appropriate, in an APOE ε4-enriched population of older adults (60–79 years) at increased risk of dementia.Methods: MET-FINGER is an international randomised, controlled, parallel-group, phase-IIb proof-of-concept clinical trial, where metformin is included through a trial-within-trial design. 600 participants will be recruited at three sites (UK, Finland, Sweden). Participants at increased risk of dementia based on vascular risk factors and cognitive screening, will be first randomised to the FINGER 2.0 intervention (lifestyle + metformin if eligible; active arm) or to receive regular health advice (control arm). Participants allocated to the FINGER 2.0 intervention group at risk indicators of T2D will be additionally randomised to receive metformin (2000 mg/day or 1000 mg/day) or placebo. The study duration is 2 years. The changes in global cognition (primary outcome, using a Neuropsychological Test Battery), memory, executive function, and processing speed cognitive domains; functional status; lifestyle, vascular, metabolic, and other dementia-related risk factors (secondary outcomes), will be compared between the FINGER 2.0 intervention and the control arm. The feasibility, potential interaction (between-groups differences in healthy lifestyle changes), and disease-modifying effects of the lifestyle-metformin combination will be exploratory outcomes. The lifestyle intervention is adapted from the original FINGER trial (diet, physical activity, cognitive training, monitoring of cardiovascular/metabolic risk factors, social interaction) to be consistently delivered in three countries. Metformin is administered as Glucophage®XR/SR 500, (500 mg oral tablets). The metformin/placebo treatment will be double blinded. Conclusion: MET-FINGER is the first trial combining a multimodal lifestyle intervention with a putative repurposed disease-modifying drug for cognitive impairment prevention. Although preliminary, its findings will provide crucial information for innovative precision prevention strategies and form the basis for a larger phase-III trial design and future research in this field.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
653 a Alzheimer’s
653 a APOE
653 a Cognitive impairment
653 a Dementia prevention
653 a Drug repurposing
653 a Lifestyle intervention
653 a Lifestyle-drug combination therapy
653 a Metformin
653 a World-Wide FINGERS
653 a Psychology
653 a Psykologi
653 a Psykologi
7001 a Lehtisalo, Jenniu Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, 70211, Kuopio, Finland; Population Health Unit, Finnish Institute for Health and Welfare, Mannerheimintie 166, P.O. Box 30, Helsinki, Finland4 aut
7001 a Perera, Dinithiu The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, W6 8RP, UK; FINGERS Brain Health Institute, C/O Stockholms Sjukhem, Box 122 30, SE-102 26, Stockholm, Sweden,The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom; FINGERS Brain Health Institute, C/O Stockholms Sjukhem, Box 122 30, Stockholm, Sweden4 aut
7001 a Aspö, Malinu Karolinska Institutet4 aut
7001 a Cross, Maryu Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine, Imperial College London, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, UK,Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine, Imperial College London, Imperial College London, Stadium House, 68 Wood Lane, London, United Kingdom4 aut
7001 a De Jager Loots, Celeste A.u The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, LondonLondon, W6 8RP, UK,The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom4 aut
7001 a Falaschetti, Emanuelau Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine, Imperial College London, Imperial College London, Stadium House, 68 Wood Lane, London, W12 7RH, UK,Imperial Clinical Trials Unit, School of Public Health, Faculty of Medicine, Imperial College London, Imperial College London, Stadium House, 68 Wood Lane, London, United Kingdom4 aut
7001 a Friel, Naomiu The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, LondonLondon, W6 8RP, UK,The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom4 aut
7001 a Luchsinger, José A.u Departments of Medicine and Epidemiology, Columbia University Irving Medical Center, 622 W 168Th St, NY, New York, United States4 aut
7001 a Malmberg Gavelin, Hanna,d 1982-u Umeå universitet,Institutionen för psykologi,Department of Psychology, Umeå University, 901 87, Umeå, Sweden4 aut0 (Swepub:umu)haamag02
7001 a Peltonen, Markkuu Population Health Unit, Finnish Institute for Health and Welfare, Mannerheimintie 166, P.O. Box 30, Helsinki, Finland; FINGERS Brain Health Institute, C/O Stockholms Sjukhem, Box 122 30, SE-102 26, Stockholm, Sweden4 aut
7001 a Price, Geraintu The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, LondonLondon, W6 8RP, UK,The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom4 aut
7001 a Stigsdotter Neely, Anna,d 1961-u Karlstads universitet,Luleå tekniska universitet,Hälsa, medicin och rehabilitering,Department of Social and Psychological Studies, Karlstad University, Karlstad, Sweden; Department of Health, Education and Technology, Luleå University of Technology, 971 87, Luleå, Sweden,Institutionen för sociala och psykologiska studier (from 2013)4 aut0 (Swepub:kau)annaneel
7001 a Thunborg, Charlottau Karolinska Institutet4 aut
7001 a Tuomilehto, Jaakkou Population Health Unit, Finnish Institute for Health and Welfare, Mannerheimintie 166, P.O. Box 30, Helsinki, Finland; Department of Public Health, University of Helsinki, PO BOX 20, 00014, Helsinki, Finland; Diabetes Research Group, King Abdulaziz University, 21589, Jeddah, Saudi Arabia4 aut
7001 a Mangialasche, Francescau FINGERS Brain Health Institute, C/O Stockholms Sjukhem, Box 122 30, SE-102 26, Stockholm, Sweden; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A, 171 64, Solna, Sweden; Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Karolinska Vägen 37A, 171 76, Solna, Sweden4 aut
7001 a Middleton, Lefkosu The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, LondonLondon, W6 8RP, UK; Directorate of Public Health, Imperial College NHS Healthcare Trust Hospitals, Praed Street, London, W2 1NY, UK,The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom; Directorate of Public Health, Imperial College NHS Healthcare Trust Hospitals, Praed Street, London, United Kingdom4 aut
7001 a Ngandu, Tiiau Population Health Unit, Finnish Institute for Health and Welfare, Mannerheimintie 166, P.O. Box 30, Helsinki, Finland; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A, 171 64, Solna, Sweden4 aut
7001 a Solomon, Alinau Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, 70211, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, W6 8RP, UK; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A, 171 64, Solna, Sweden,Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A, Solna, Sweden4 aut
7001 a Kivipelto, Miiau The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, LondonLondon, W6 8RP, UK; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A, 171 64, Solna, Sweden; Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Karolinska Vägen 37A, 171 76, Solna, Sweden; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1C, 70211, Kuopio, Finland,The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom; Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska Vägen 37A, Solna, Sweden; Theme Inflammation and Aging, Medical Unit Aging, Karolinska University Hospital, Karolinska Vägen 37A, Solna, Sweden; Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1C, Kuopio, Finland4 aut
7102 a Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, 70211, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, W6 8RP, UKb Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Yliopistonranta 1C, Kuopio, Finland; The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, Charing Cross Hospital, St Dunstan’s Road, London, United Kingdom4 org
7730 t Alzheimer's Research & Therapyd : BioMed Central Ltdg 16q 16x 1758-9193
8564 u https://doi.org/10.1186/s13195-023-01355-xy Fulltext
8564 u https://ltu.diva-portal.org/smash/get/diva2:1837878/FULLTEXT02.pdfx primaryx Raw objecty fulltext:print
8564 u https://umu.diva-portal.org/smash/get/diva2:1837082/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 u https://kau.diva-portal.org/smash/get/diva2:1839147/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:ltu:diva-104290
8564 8u https://doi.org/10.1186/s13195-023-01355-x
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-220751
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:kau:diva-98616
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154774109

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy